MedTrace Logo

Treatment of Schizoaffective Disorder Using Mifepristone

NCT00725270 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-03-24

Study results available
· View outcomes & findings →

Summary

This study tests the hypothesis that mifepristone will diminish cognitive distortion and alleviate psychosis in patients with schizoaffective disorder.

Conditions

  • Psychotic Disorders
  • Depressive Disorder, Major
  • Depressive Disorder

Interventions

DRUG

Mifepristone

600 mg of mifepristone

DRUG

Placebo Oral Tablet

Placebo comparator

Sponsors & Collaborators

Principal Investigators

  • Jennifer Keller · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-04-30
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00725270 on ClinicalTrials.gov